Exenatide (Byetta): first in another new class of diabetes drugsExenatide (Byetta): first in another new class of diabetes drugs

Published 2010-08-01 00:00:00

Exenatide is an injectable drug in the new class of incretin mimetics, PBS listed from 1 August 2010 for type 2 diabetes. The listing is for combination therapy as either:
  • dual therapy, with metformin or a sulfonylurea, where HbA1c exceeds 7% and the patient cannot take these drugs together, or
  • triple therapy, with metformin and a sulfonylurea, where HbA1c exceeds 7% despite maximally tolerated doses of both drugs.
An in-depth NPS RADAR review of exenatide will be published online before our December print issue. To receive the exenatide review as soon as it is available, subscribe to the NPS RADAR email alert.

RSS FeedRSS feed

Date published: 2010-08-01 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.